Cargando…
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
Autores principales: | Prince, FHM, Twilt, M, Simon, SCM, van Rossum, MAJ, Armbrust, W, Hoppenreijs, EPAH, Kamphuis, SSM, van Santen-Hoeufft, M, Koopman-Keemink, Y, Wulffraat, N, ten Cate, R, van Suijlekom-Smit, LWA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334100/ http://dx.doi.org/10.1186/1546-0096-6-S1-P40 |
Ejemplares similares
-
Development of a web-based register for the Dutch national study on biologicals in juvenile idiopathic arthritis: http://www.abc-register.nl
por: Prince, FHM, et al.
Publicado: (2008) -
Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011) -
Long term functional outcome and quality of life of patients with refractory juvenile idiopathic arthritis treated with etanercept: results of the dutch arthritis and biologicals in children register
por: Anink, Janneke, et al.
Publicado: (2014) -
PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register
por: Otten, MH, et al.
Publicado: (2013) -
PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
por: Anink, J, et al.
Publicado: (2013)